广生堂(300436) - 2025 Q1 - 季度财报

Financial Performance - The company's revenue for Q1 2025 was ¥97,607,995.93, a decrease of 18.69% compared to ¥120,047,604.86 in the same period last year[4] - The net loss attributable to shareholders was ¥28,488,936.37, representing a 94.56% increase in losses from ¥14,642,717.07 year-on-year[4] - The basic earnings per share were -¥0.1789, a decline of 94.67% compared to -¥0.0919 in the previous year[4] - Net loss for the period was ¥29,523,406.44, compared to a net loss of ¥14,706,929.43 in the previous period, indicating a significant increase in losses[19] - The total comprehensive loss for the period was ¥29,523,406.44, compared to a comprehensive loss of ¥14,706,929.43 in the previous period[19] Assets and Liabilities - The total assets at the end of the reporting period were ¥1,383,018,070.86, down 3.88% from ¥1,438,807,956.07 at the end of the previous year[4] - The company's total assets decreased to ¥1,383,018,070.86 from ¥1,438,807,956.07, a decline of approximately 3.9%[17] - Total liabilities decreased to ¥1,015,763,555.73 from ¥1,042,030,034.50, a reduction of about 2.5%[17] - The equity attributable to the parent company decreased to ¥331,689,887.35 from ¥360,178,823.72, a decline of approximately 7.9%[17] Cash Flow - The net cash flow from operating activities was -¥12,553,020.77, showing a slight improvement of 5.05% from -¥13,220,727.89 year-on-year[4] - Operating cash inflow totaled $116,544,042.68, down from $133,553,914.09 in the previous period, representing a decrease of approximately 12.7%[21] - Cash outflow from operating activities was $129,097,063.45, compared to $146,774,641.98 in the prior period, indicating a reduction of about 12.1%[21] - Net cash flow from investment activities was -¥11,484,015.64, a 38.28% decline compared to -¥8,304,797.49 in the previous year[7] - Cash inflow from financing activities was $53,000,000.00, down from $98,000,000.00 in the prior period, a decline of about 46.0%[22] Operating Expenses and Income - The company reported a significant increase in operating expenses, with a 30.73% decrease in operating costs to ¥33,548,692.35 due to lower revenue[6] - The company reported an operating loss of ¥27,172,651.26, compared to an operating loss of ¥14,982,821.03 in the previous period[19] - The company experienced a 1021.68% increase in income tax expenses, amounting to ¥2,440,975.68, primarily due to profits from its subsidiary[7] - The company reported a 248.57% increase in other operating income to ¥222,926.10, attributed to compensation and penalties received[6] Shareholder Information - The total number of common shareholders at the end of the reporting period is 14,003[9] - The largest shareholder, Fujian Aohua Group Co., Ltd., holds 17.00% of shares, totaling 27,068,651 shares, with 20,110,000 shares pledged[9] Research and Development - The company received approval for a Phase II clinical trial of innovative drug GST-HG131 combined with GST-HG141, which will shorten the review and approval cycle[12] - Research and development expenses decreased to ¥6,102,198.78 from ¥7,211,260.72, a reduction of about 15.4% year-over-year[18] Inventory and Assets Changes - The company’s cash and cash equivalents decreased from 143,954,066.36 RMB to 119,506,606.67 RMB, a decline of approximately 16.9%[15] - Inventory increased from 114,475,159.49 RMB to 121,132,863.31 RMB, reflecting a growth of about 5.8%[15] - The company’s long-term equity investments decreased from 80,177,607.81 RMB to 79,100,550.01 RMB, a decline of approximately 1.3%[15] - The company’s total current assets decreased from 407,299,897.31 RMB to 378,047,943.80 RMB, a decline of about 7.2%[15] - The company’s fixed assets decreased from 558,261,569.72 RMB to 545,778,456.17 RMB, a decline of approximately 2.2%[15] - The company’s intangible assets decreased from 251,655,214.92 RMB to 246,276,434.62 RMB, a decline of about 2.1%[15]